Search

Displaying results 571 - 580 of 4627 in total
  1. Drug

    Filgrastim

    go.drugbank.com/drugs/DB00099
    ApprovedInvestigational

    It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. … Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology.

  2. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    by Merck in 2019). … [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers.

  3. Drug

    Inosine

    go.drugbank.com/drugs/DB04335
    Approved

    A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose.

  4. Drug

    Activated charcoal

    go.drugbank.com/drugs/DB09278
    ApprovedInvestigational

    It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances … It works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time.

  5. Drug

    Diphenylpyraline

    go.drugbank.com/drugs/DB01146
    Approved

    Antihistamines prevent, but do not reverse, responses mediated by histamine alone. … Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells.

  6. Drug

    Griseofulvin

    go.drugbank.com/drugs/DB00400
    ApprovedVet approved

    Griseofulvin may be given by mouth in the treatment of tinea infections.

  7. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019. … [L34485] The use of semaglutide in weight management is also approved by Health Canada [L39347] and the EMA.

  8. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    of illnesses caused by other protozoa or helminths [A31976]. … Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment

  9. Drug

    Hydroxyprogesterone caproate

    go.drugbank.com/drugs/DB06789
    Approved

    Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S.

  10. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow.